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Background: Surgery remains the only curative option for the treatment of pancreatic adenocarcinoma (PDAC).
The goal of this study was to investigate the clinical outcome and prognostic factors in patients after resection for
ductal adenocarcinoma of the pancreatic head.
Methods: The data from 195 patients who underwent pancreatic head resection for PDAC between 1993 and 2011
in our center were retrospectively analyzed. The prognostic factors for survival after operation were evaluated using
multivariate analysis.
Results: The head resection surgeries included 69.7% pylorus-preserving pancreatoduodenectomies (PPPD) and
30.3% standard Kausch-Whipple pancreatoduodenectomies (Whipple). The overall mortality after
pancreatoduodenectomy (PD) was 4.1%, and the overall morbidity was 42%. The actuarial 3- and 5-year survival
rates were 31.5% (95% CI, 25.04%-39.6%) and 11.86% (95% CI, 7.38%-19.0%), respectively. Univariate analyses
demonstrated that elevated CEA (p = 0.002) and elevated CA 19–9 (p = 0.026) levels, tumor grade (p = 0.001) and
hard texture of the pancreatic gland (p = 0.017) were significant predictors of a poor survival. However, only CEA
>3 ng/ml (p < 0.005) and tumor grade 3 (p = 0.027) were validated as significant predictors of survival in
multivariate analysis.
Conclusions: Our results suggest that tumor marker levels and tumor grade are significant predictors of poor
survival for patients with pancreatic head cancer. Furthermore, hard texture of the pancreatic gland appears to be
associated with poor survival.
Keywords: Pancreatic cancer, Tumor marker, Surgery, Whipple procedure, Pylorus-preserving
pancreatoduodenectomy (PPPD)Background
The prognosis for patients with cancer of the pancreatic
head remains poor. Currently, tumor resection is the
only therapeutic option to achieve long-term survival.
However, only a small number of patients (30-40%)
present a resectable tumor at the time of diagnosis. The
overall 5-year survival after pancreatic head resection for
cancer ranges between 10 and 25% [1-3]. Adjuvant
chemotherapy, which improves patient survival, is rou-
tinely used [4,5]. The following characteristics have been* Correspondence: marius.distler@uniklinikum-dresden.de
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reproduction in any medium, provided the orreported to be significant prognostic factors for patient
survival after tumor resection: age, tumor size, nodal
and margin status and tumor grade [2,6-8]. Pancreatic
surgery, specifically pancreatoduodenectomy (PD), has
been identified to be a ‘formidable’ operation in earlier
years [9]. The operation can be performed safely, and
postoperative mortality in some specialized pancreatic
centers is currently less than 5% [10,11].
Reduced mortality was achieved by concentrating pan-
creatic surgeries in specialized centers because pancre-
atic surgery is technically demanding and places high
demands on the perioperative management [12,13].
Another important factor for reducing mortality and
morbidity is better patient selection. Clinical decision-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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based medicine [14].
The 5-year survival rate can be significantly improved
for patients with pancreatic cancer when surgery is pos-
sible. However, some patients relapse shortly after the
resection and exhibit a limited life span even after R0
resection.
To better assess the risks and benefits of surgical treat-
ment, it is necessary to analyze the factors that might in-
fluence or determine which patients have limited
survival.
The present study reports the short- and long-term
outcome of 195 consecutive pancreatic head resections
due to pancreatic cancer from a single German pancre-
atic center. Univariate and multivariate analyses were
performed to examine the factors affecting survival.Methods
Patients
Eight fellowship-trained pancreatobiliary surgeons per-
formed 672 consecutive PDs between October 1993 and
November 2008 in our department; the period of obser-
vation was 1993 to 2011. We excluded patients who
underwent palliative bypass or pancreatic resections for
pancreatic cancer in the body and tail of the pancreas,
distal cholangiocarcinoma, duodenal carcinoma, neuro-
endocrine tumors, cyst-adenocarcinoma, solid and papil-
lary tumors, and metastatic tumors. The final pathological
diagnosis confirmed ductal pancreatic adenocarcinoma
(PDAC) in 195 (29%) of the remaining patients. The
demographic characteristics are summarized in Table 1.Table 1 Patient cohort demographic and clinical data
(n = 195)
n=
Sex (m/f) 103 (53%)/92 (47%)
Age y (±SD) 67.0 (± 9.7) 95% CI 63.3-66.1
Hypertension (yes/no) 100 (51.3%)/95 (48.7%)
Preoperative diabetes mellitus
(yes/no) 69 (35.4%)/126 (64.6%)
Obstructive jaundice (yes/no) 159 (81.5%)/36 (18.5%)
Preoperative biliary stent (yes/no) 139 (71.3%)/56 (28.7%)
Alcohol abuse (yes/no) 64 (32.8%)/131 (67.2%)
Nicotine abuse (yes/no) 35 (17.9%)/160 (82.1%)
Pack-years (±SD) 20 (± 6.5 y)





The head resection surgeries analyzed in the study in-
cluded 69.7% pylorus-preserving pancreatoduodenectomies
(PPPD) and 30.3% standard Kausch-Whipple pancrea-
toduodenectomies (Whipple). The decision for one of the
approaches (either Whipple or PPPD) was made during
the operation. The primary goal of every operation was en
bloc R0 tumor resection. In all the patients, a lymphade-
nectomy was performed along the hepatoduodenal liga-
ment, common hepatic artery, vena cava, interaortocaval
and right side of the superior mesenteric artery. In cases
with portal vein involvement, a venous resection was
performed to achieve R0-resection. Patients with arterial
infiltration by the tumor were stated to be locally
irresectable. Thrombosis of the portal vein was always a
contraindication for pancreatic head resection. The two-
layer invagination technique was used for pancreatic anas-
tomosis in all the cases as previously described [14]. We
routinely placed drains intraoperatively. All the patients
were staged preoperatively with CT and/or MRI and
transabdominal ultrasound, and the PD patients were rou-
tinely observed at the Intensive Care Unit (ICU). The
drains were removed after exclusion of a postoperative
pancreatic fistula (POPF). Postoperative complications
were treated symptomatically.
Data collection
The medical records from a prospective database of pa-
tients who underwent PDs for PDAC were analyzed
retrospectively for each case. In accordance with the
guidelines for human subject research, approval was
obtained from the Ethics Committee at the Carl Gustav
Carus University Hospital. All the operated patients
singed inform consent agreements before surgery. The
survey data were complemented with the clinical notes
of the patients’ physicians and surgeons. Details regard-
ing the deceased patients were obtained from family
members or from the general practitioner. The postoper-
ative follow-up time was three years or until the death of
the patient.
Patient characteristics and parameters used for statis-
tical analysis are listed in the supplementary information
(Additional file 1: Table S1). The postoperative events
and clinical outcomes were recorded prospectively and
analyzed retrospectively. The tumor-stage designation
was categorized according to the TNM system of the
Union Internationale Contre le Cancer (UICC 2007).
Definitions
Perioperative mortality was defined as in-hospital mor-
tality. Postoperative pancreatic hemorrhage (PPH) was
categorized according to the ISGPS consensus definition.
[15]. Delayed gastric emptying (DGE) was classified
according to the definition suggested by the ISGPS [16].
Table 2 Indications for operations and performed
procedures (n = 195)
Indication for operation*
Pain (%) 1.5
Suspicion of malignancy (%) 98.5
Obstructive jaundice (%) 20.0




Resection of the SMV/portal vein (%) 29.7
Mean operative time (minutes) SD 420.88 ± 99.0
Postoperative hospital stay (days) 19.02 (range 7–100)
Postoperative ICU stay (days) 5.24 (range 0–69)
*Multiple answers were possible.
(SMV, Superior mesenteric vein; PPPD, Pylorus-preserving
pancreaticoduodenectomy; ICU, Intensive care unit).
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according to the ISGPF criteria [17].
Statistical analysis
The statistical analyses were performed using SPSS for
Windows, version 15.0 (SPSS, Inc., Chicago, IL). All clin-
ical and pathological characteristics were stratified to
build categorical or nominal variables. CEA and CA19-9
were grouped according to the cutoff values used in our
center (cut-off levels CEA and CA 19–9: ≤3 ng/ml and
≤75 U/ml). Other variables such as age and BMI were
grouped according to previous publications [8]. The
thresholds used for categorization were based on previ-
ously described thresholds in the literature and/or recur-
sive partitioning as previously described [18]. Continuous
data are presented as 95% confidence intervals (95% CI)
and standard deviation (SD). The univariate examin-
ation of the relationship between the assessed criteria
and survival was performed with a χ2-test. To assess the
impact of the different parameters on survival, we uti-
lized a 3-year survival rate. The estimates of patient sur-
vival were generated using the Kaplan-Meier method.
The comparisons of survival were performed using the
log-rank test. Student’s t-tests (ratio scale) and Fisher’s
exact tests (ordinal scale) were utilized for comparisons
between groups. Ordinal-scaled variables were com-
pared using the chi-square test. Significant factors (at P
< 0.10) at the univariate level were entered into the
multivariate model. A Cox regression analysis with step-
wise backwards elimination based on the likelihood ra-
tios was employed to test for independent predictors of
survival. A p-value <0.05 was considered significant.
Results
Patient demographics and preoperative parameters
From 1993 to 2008, 195 patients underwent pancreatic
head resections (PD) due to ductal adenocarcinoma of
the pancreas at our institution. The patients were ob-
served from 1993 to 2011. The patient characteristics
are described in Table 1. An obstructive jaundice
appeared on average 4 weeks before the operation (±
2.3 weeks) in 159 patients (81.5%), and 139 of the pa-
tients were preoperatively treated with a biliary stent
(71.3%). The maximal bilirubin concentration was
17.26 mg/dl (± 15.9 mg/dl). Weight loss was observed in
119 (61.0%) patients, and the average preoperative
weight loss was 8.55 kg (± 4.57 kg). The average onset of
weight loss was 8.0 weeks before the operation (±
9.8 weeks).
Intraoperative parameters
In most of the cases, the indication for operation was
suspicion of malignancy (98.5%). The median postopera-
tive hospital stay was 19.02 days (range 7–100) andincluded a median postoperative ICU stay of 5.2 days
(range 0–69). In 29.7% of the cases, a partial resection of
the portal vein (or superior mesenteric vein) was neces-
sary. The mean duration of the pancreatic resection was
420.88 ± 99.0 minutes (range: 234–874 min) (Table 2).Morbidity and mortality
The occurrence of perioperative mortality was 4.1% (8
patients) in the 195 patients who underwent resection
for pancreatic cancer. During the postoperative course,
81 patients (42%) developed one or more complications.
Most of the complications were minor (30%).
Grade B delayed gastric emptying was observed in 13
patients (6.7%), and grade C delayed gastric emptying
was observed in 5 patients (2.6%). Ten patients devel-
oped grade B (5.1%) POPF, and 3 patients developed
grade C POPF (1.5%). Grade B PPH was observed in 5
patients (2.6%), and grade C PPH was observed in three
patients (1.5%). Table 3 presents the morbidity and mor-
tality after PD.
Forty-eight of the patients developed one complica-
tion, 18 patients developed two complications, seven pa-
tients developed three complications, and eight patients
developed more than three complications.Histological analysis of the specimen
The tumor stage was pT1 in 7 (3.6%) patients, pT2 in 12
(6.1%) patients, pT3 in 173 (88.8%) patients and pT4 in
3 (1.5%) patients; the most frequent postoperative UICC
2002 stages were IIa and IIb. In 138 cases (70.8%), an R0
resection was certified by pathohistological examination
of the specimen (R1: n = 42 (21.5%); R2: n = 10 (5.1%);
Rx: n = 5 (2.6%)). Nodal disease was diagnosed in 129
(66.2%) of the 195 patients, 66 (33.8%) patients were
Table 3 Morbidity/outcome after PD due to PDAC of the
pancreatic head
Complication/morbidity Patients with complication*
n = 81 (42%)
POPF
Grade B n = 10 (5.1%)
Grade C n = 3 (1.5%)
PPH
Grade B n = 5 (2.6%)
Grade C n = 3 (1.5%)
DGE
Grade B n = 13 (6.7%)
Grade C n = 5 (3.6%)
Other complications
Wound infections n = 30 (15.4%)
Postoperative pneumonia n = 10 (5.1%)
Pancreatitis n = 8 (4.1%)
Cholangitis n = 3 (1.5%)
Urinary tract infection n = 7 (3.6%)
Anastomotic leakage
Hepaticojejunostomy n = 8 (4.1%)
Pancreatojejunostomy n = 16 (8.2%)
In-hospital mortality n = 8 (4.1%)
*Multiple answers were possible.
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and 5 (2.6%) patients had a pN1b status. In 15 patients,
an M1 situation was confirmed in the final pathological
evaluation. In all the cases, the M1 status was due to
interaortocaval lymph nodes (Table 4).
The PDAC was well differentiated (G1) in 6 (3.1%) pa-
tients, intermediately differentiated (G2) in 102 (52.3%)
patients, poorly differentiated (G3) in 82 (42.0%) patients
and undifferentiated (G4) in 5 (2.6%) patients (Table 4).Survival
To date, 163 of the 195 patients have died; 16 of the pa-
tients have died due to other causes and were censored
for the survival analysis. The actuarial 3- and 5-year sur-
vival rates were 31.5% (95% CI, 25.04%-39.6%) and
11.86% (95% CI, 7.38%-19.0%), respectively. The median
overall survival was 17.08 months (95% CI, 14.0%-20.1%)
(Figure 1).
Adjuvant therapy was not routinely used in our center
until 2003. Seventy-nine (40.5%) of the patients received
postoperative adjuvant therapy. The median survival for
patients without adjuvant CTx was 16.4 months (95%
CI, 11.6- 21.2), and the median survival was 21.0 months
(95% CI, 14.2-27.9) for patients with adjuvant CTx,
which was not significant (p = 0.931).Univariate survival analysis
In the univariate analysis, we correlated different param-
eters with the 3-year survival rate. CEA >3 ng/ml (p =
0.002), CA 19–9 >75 U/ml (p = 0.026) levels, tumor
grade 3 (p = 0.001) and hard texture of the pancreatic
gland (p = 0.017) were identified as significant predictive
factors of poor patient survival. The lymph node ratio,
T-stage or R-status (R1/R2 resection) were not found to
be significant factors in univariate analysis. Table 5 sum-
marizes the findings of the univariate analysis.Multivariate survival analysis
All the factors that were significant in the univariate
analyses at the p < 0.10 level (CEA, CA 19–9, age, tex-
ture of the pancreas and tumor grade) were tested using
multivariate analysis. However, only the CEA level
>3 ng/ml (p < 0.001) and tumor grade 3 (p = 0,013) could
be identified as independent risk factors for patient sur-
vival (HR 2.350 and 1.346, respectively) (Table 6).
Figure 1 Kaplan-Meier analysis of overall survival of patients
with PDAC of the pancreatic head after PD; the 3- and 5-year
survival rates were 31.5% (95% CI, 25.04%-39.6%) and 11.86%
(95% CI, 7.38%-19.0%), respectively.
Table 5 Univariate analysis of factors that influenced 3-
year survival after PD due to PDAC of the pancreatic
head
3-year survival p Value
Age (years) 0.073
<60 (n = 74) n = 22 (30%)
61-65 (n = 100) n = 18 (18%)
>65 (n = 21) n = 2 (9%)
CEA (ng/ml) 0.002
<4 (n = 151) n = 39 (26%)
>4 (n = 36) n = 1 (3%)
CA 19–9 (U/ml) 0.026
<24 (n = 39) n = 13 (33%)
>24 (n = 151) n = 26 (17%)
T- stage 0.894
pT1 n = 7 n = 2 (28%)
pT2 n = 12 n = 2 (17%)
pT3 n = 173 n = 37 (21%)
pT4 n = 3 n = 1 (33%)
R-status 0.155
R0 n = 138 n = 30 (22%)
R1 n = 42 n = 8 (19%)
R2 n = 10 n = 1 (10%)
Lymph node-ratio 0.709
<0.2 (n = 134) n = 30 (22%)
≥0.2 (n = 60) n = 12 (20%)
Tumor grade 0.001
G1 (n = 6) n = 4 (67%)
G2 (n = 102) n = 21 (20%)
G3 (n = 82) n = 12 (15%)
G4 (n = 5) n = 2 (40%)
Pancreas texture 0.017
Hard n = 33 n = 2 (6%)
Soft n = 161 n = 40 (25%)
Preoperative diabetes (n = 69) n = 12 (17%) 0.365
Nicotine abuse (n = 35) n = 6 (17%) 0.651
Hypertension (n = 100) n = 18 (18%) 0.163
BMI >35 (n = 3) 0 0.631
POPF grade B (n = 10) n = 4 (40%) 0.228
POPF grade C (n = 3) n = 1 (33%) 0.387
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In the present study, we retrospectively analyzed the
long-term survival of patients undergoing PD for carcin-
oma of the pancreatic head in a single, high-volume cen-
ter. The aim of this study was to identify predictive
factors for long-term survival. The characteristics of the
patient cohort were similar to previous reports [12,19].
The head resections included PPPD and Whipple proce-
dures. The most common indication for operation was
suspected malignancy, and most of the patients
presented obstructive jaundice due to a tumor in the
pancreatic head. All the patients exhibited histologically
confirmed PDAC in the final examination of the
specimen.
We observed a perioperative mortality of 4.1% in our
study group, which was within the range of previous re-
ports and indicates that the procedure is safe when
performed in a hospital setting [12,19,20]. Surgical com-
plications were observed in 42% of the patients undergo-
ing PD. The high morbidity might have resulted from
our comprehensive data acquisition. Our prospective
pancreatic database includes surgical and unspecific
complications. Most of the analyzed complications
exhibited only minor effects on patient health such as
wound infection, which was the most common surgical
complication, or delayed gastric emptying (DGE). Severe
complications (as defined by the ISGPS), such as grade
C POPF, PPH or anastomotic leakage, were observed in
10% (n = 19) of the patients (Table 3). The complication
rate is similar to previous studies [12,19]. Consideringthe complication rate, the indication for pancreatic re-
section should be performed carefully.
During univariate analyses, the elevated tumor marker
levels of CEA and CA 19–9, the texture of the pancreas
(hard) and the tumor grade (grade 3) were identified as
significant factors with negative prognostic effects on pa-
tient survival. Multivariate analysis demonstrated that a
Table 6 Multivariate analysis of factors that influenced 3-year survival in patients after PD for PDAC of the pancreatic
head
HR 95% Confidence Interval HR P value
Lower Upper
Step 1 Age 1.205 0,916 1,549 0.162
CEA >3 ng/ml 2.293 1,488 3,628 <0.001
CA 19–9 >75 U/ml 1.130 0,721 1,671 0.560
Tumor-grade 3 1.312 1,032 1,685 0.027
Pan. Texture (hard) 1.046 0,590 1,713 0.866
Step 2 Age 1.203 1,489 3,626 0.164
CEA >3 ng/ml 2.297 0,916 1,547 <0.001
CA 19–9 >75 U/ml 1.136 0,724 1,667 0.539
Tumor-grade 3 1.313 1,032 1,685 0.027
Step 3 Age 1.215 0,917 1,547 0.142
CEA >3 ng/ml 2.258 1,490 3,627 <0.001
Tumor-grade 3 1.330 1,035 1,683 0.565
Step 4
CEA >3 ng/ml 2.350 1,518 3,639 <0.001
Tumor-grade 3 1.346 1,064 1,702 0.013
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0,027) were independent predictive factors for patient
survival. CEA and CA19-9 are the most studied serum
tumor markers for the diagnosis and prognosis of pan-
creatic adenocarcinoma [21]. CEA is known to exhibit
low sensitivity in screening PDAC [22]. However, other
authors hypothesized that high levels might be associ-
ated with the existence of occult metastasis or locally ad-
vanced diseases in patients with PDAC. Therefore,
previously high levels of CEA could be associated with
incurability in patients with pancreatic cancer [23,24].
Although CEA might not be appropriate for screening,
its serum level should be determined in patients prior to
operation. High serum levels of CEA should be consid-
ered by the surgeon in cases where respectability or op-
erability is questionable.
Levels of carbohydrate antigen (CA) 19–9, a tumor-
associated glycoprotein, are elevated in approximately
85% of patients with PDAC [25], and serum CA19-9
measurements can be used for diagnostic purposes (i.e.,
as a predictor of resectability or as a marker of recurrent
disease after resection) [26]. Both CA19-9 and CEA can
be used to predict survival after pancreatic resection
[27,28]. In an analysis by Hartwig et al., CA-19-9 levels
greater than 400 U/ml were identified as one of the
strongest negative survival predictors [29]. However,
cholestasis is known to influence serum tumor marker
concentrations. Both CA19-9 and CEA undergo biliary
excretion, and serum levels may artificially increase due
to biliary obstruction caused by cancer masses [30]. Be-
cause many patients experienced obstructive jaundice inour study cohort, our results, particularly the CA19-9
results, may be biased. However, in multivariate analysis,
CA19-9 could not be identified as a significant predictor
of survival in patients with PDAC.
According to our data, tumor differentiation plays a
prominent role for survival in pancreatic cancer, as
already shown in other tumor entities. Tumor differenti-
ation was an independent prognostic factor in multivari-
ate analysis [1,8,31]. Contrary to these results, we did
not observe an influence of the TNM classification or
the resectional status, similarly to previous publications
[1,8]. It is unclear why these parameters were not corre-
lated with survival. Data published by Esposito et al. sug-
gest that most resections in pancreatic cancer are R1
resections [32]. As a result, other researchers in this field
refer to pancreatic cancer as a “systemic disease”. While
the classification as a systemic disease may be immoder-
ate for a solid tumor, it shows that aggressive infiltration
and metastasizing are important hallmarks of pancreatic
cancer. These hallmarks might be more pronounced in
tumors with poor differentiation, which might also ex-
plain why our results did not identify the lymph node ra-
tio as a significant factor as previously published by
Riediger et al. The lymph node ratio may be diagnostic-
ally relevant similar to other tumor entities. However,
tumor grading appears be a more relevant indicator of
the patient’s prognosis as shown in our analysis.
Furthermore, the texture of the pancreas was identi-
fied to be a predictor of survival in our analysis. Soft tex-
ture of the gland was related to a good prognosis (p <
0.017). This sudden finding is especially difficult to
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in a fibrotic pancreas compared with a soft and friable
normal pancreas with a narrow main pancreatic duct
[14,33]. In patients with a soft pancreas, chronic pan-
creatitis is usually not present, and the patients may ex-
hibit better organ function, which results in a better
prognosis. Tumors derived from a chronic pancreatitis
(associated with hard texture) were more aggressive or
exhibited more aggressive pathophysiology than carcin-
omas arising from a normal pancreas. Because no sig-
nificance for the texture was shown in the multivariate
analysis, the parameter might be a surrogate for another
variable influencing outcome. Furthermore, the evalu-
ation of pancreatic texture must be considered, espe-
cially in retrospective analyses, because it is very
subjective and easy to overestimate.
The actuarial overall 3- and 5-year survival rates were
31.5% (95% CI, 25.04%-39.6%) and 11.86% (95% CI,
7.38%-19.0%), respectively. These findings are similar to
those reported in the literature [1,12,29]. There was no
statistical significance between the subgroups of patients
with or without adjuvant chemotherapy [median sur-
vival: without adjuvant CTx 16.4 months (95% CI, 11.6-
21.2 months) vs. with adjuvant CTx 21.0 months (95%
CI, 14.2-27.9 months) (p = 0.931)], which may be due to
the heterogeneity of the chemotherapeutic regimes. Ap-
proximately 50% of our patients received adjuvant
chemotherapy (i.e., mainly with gemcitabine). Although
long-term survival may be achieved in only a minority of
patients, the complete surgical resection of pancreatic
adenocarcinoma represents the only potential curative
option.Conclusion
In our single-center analysis, CEA tumor marker levels
and tumor grade were identified as significant predictors
for poor survival in patients with pancreatic head cancer.
However, hard texture of the pancreatic gland appears to
exhibit an indirect positive effect on patient survival
after pancreatic head resection, but the reason for the ef-
fect remains unclear.Additional file
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